Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

EDP Renewables Starts Construction on 240-Megawatt Texas Solar Park

Bristol Myers (BMY) gets EC approval for the fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor Opdivo (nivolumab and novel LAG-3-blocking antibody relatlimab.

Bristol Myers (BMY) Skin Cancer Drug Gets EC's Approval

AbbVie

Forbes is tracking the biggest layoffs in the U.S. this summer as companies react to fears of a looming recession.

Calif. Pharmaceutical Companies AbbVie And Bristol Myers Lay Off 360—Here Are The Major U.S. Layoffs This Summer

Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%

Drugmakers Bristol Myers Squibb Co and AbbVie Inc told California officials that they plan to cut up to 360 jobs there in unrelated moves, according to notices filed with the state that were made public earlier this week.

Bristol Myers, AbbVie plan to cut up to 360 California jobs

Bristol Myers' (BMY) immuno-oncology drug Opdivo demonstrates a statistically significant and clinically meaningful improvement in recurrence-Free survival (RFS) in patients with Stage IIB/C melanoma.

Bristol Myers' (BMY) Opdivo Meets Main Goal in Melanoma Study

Amgen

Pfizer

Makers of the top selling drugs in the United States are costing patients billions of dollars and worsening a drug pricing crisis by abusing the U.S. patent system to stifle competition and inflate prices, a consumer group said on Thursday,

Consumer group says drugmakers abuse U.S. patent system to keep prices high

Investors were cheered by good news from the lab.

Why Bristol Myers Squibb Triumphed On Thursday

Bristol Myers Squibb Announces Adjuvant Treatment with Opdivo (nivolumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS) in Patients with Stage IIB/C Melanoma in the CheckMate -76K Trial

Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.

Is Most-Watched Stock Bristol Myers Squibb Company (BMY) Worth Betting on Now?

AbbVie Inc (NYSE: ABBV) is a better long-term investment than peer Bristol-Myers Squibb Co (NYSE: BMY) even though the latter just secured FDA approval for its Psoriasis pill, says Mohit Bansal. He's a Managing Director at Wells Fargo.

Bristol-Myers versus AbbVie stock: Expert picks a side

Apple

FedEx

Intel

Mastercard

Viatris

Finding stock picks to beat the market are rare finds nowadays. In September stock markets began on downbeat momentum following the S&P 500 rally throughout the summer.

7 Screaming Buy Stock Picks to Beat the September Market Slump

Bristol Myers (BMY) secures an FDA nod for Sotyktu to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Bristol Myers (BMY) Gets FDA Approval for Psoriasis Candidate

Bristol-Myers Squibb Co (NYSE:BMY ) Morgan Stanley Global Healthcare Conference September 12, 2022 8:10 AM ET Company Participants Christopher Boerner - EVP & Chief Commercialization Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Great. Good morning, everybody.

Bristol-Myers Squibb Co (BMY) Morgan Stanley Global Healthcare Conference Call Transcript

The FDA approved Sotyktu, an oral treatment for psoriasis, after a series of trials.

Bristol Myers Stock Jumps as U.S. Approves Psoriasis Drug. What It Means for the Sector.

This blue chip big pharma stock offers investors a recession-proof business, a rising top line, and a solid dividend.

Bristol Myers Squibb Is a Must-Own Stock Right Now. Here's Why.

Bristol-Meyers Squibb Co (NYSE:BMY) is up 6.4% at $74.62 at last glance and earlier traded as high as $75.99, after the U.S. Food and Drug Administration (FDA) approved Sotyktu, the company's oral treatment for plaque psoriasis.

Pharmaceutical Stock Jumps on FDA Approval

Occidental Petroleum

Good news for a big healthcare company has its stock moving higher as Wall Street looks to sustain its momentum from last week.

Buffett Still Loves Occidental, but Here's Monday's Mammoth Market Mover

Bristol-Myers Squibb (NYSE: BMY ) stock rose 8% over the weekend after the Food and Drug Administration (FDA) approved Sotyktu, its oral treatment for moderate-to-severe psoriasis. For the year BMY stock is up over 21% while the average S&P 500 stock is down by over 23%.

Bristol-Myers Squibb (BMY) Stock Jumps 8% as FDA Approves Psoriasis Treatment

Shares of drugmaker Bristol Myers Squibb rose 7% in premarket trading Monday after it said the Food and Drug Administration approved a key medication.

Bristol Myers Stock Jumps as U.S. Approves Psoriasis Drug

Bristol Myers Squibb BMY, +1.12% shares rose 7% in premarket trade after the company said the U.S. Food and Drug Administration approved Sotyktu, which the drugmaker said was the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly 10 years. Bristol Myers Squibb said the approval came after Phase 3 trials found it was more effective compared to placebo and twice-daily Otezla, made by Amgen AMGN, +0.91%.

Bristol Myers Squibb rallies after FDA approves Sotyktu for psoriasis

Archer-Daniels-Midland Company

Cigna

SPDR Dow Jones Industrial Average ETF

Ford Motor Company

First Trust NASDAQ Technology Dividend Index Fund

Figuring out which blue-chip stocks to buy before the bull market returns can be a challenge. So far, declines on Wall Street have pushed the major averages into bear market territory.

7 Blue-Chip Stocks to Buy Before the Bull Market Returns

Bristol Myers Squibb showed substantial strength in the last months compared to the market. In the last weeks, momentum began to weaken due to some mixed pipeline updates and upcoming concerns about the long-term strategy.

Bristol Myers Squibb: Still A Buy Despite Some Concerns

Bristol Myers Squibb Announces New Sotyktu™ (deucravacitinib) Long-Term Data Showing Clinical Efficacy Maintained for Up to Two Years with Continuous Treatment in Moderate-to-Severe Plaque Psoriasis

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #doctor--FDA approves SOTYKTU for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

News for Bristol-Myers Stock (BMY)